Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.45 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279517 | 0.93 | NR1H2 (0.44) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL1280144 | 0.93 | NR1H2 (0.44) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL1280145 | 0.93 | NR1H2 (0.44) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL1279513 | 0.93 | NR1H2 (0.44) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL1693087 | 0.88 | HPGD (0.50) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL4403100 | 0.88 | HPGD (0.50) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL4595961 | 0.87 | DPP4 (0.52) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL3257440 | 0.86 | HPGD (0.51) | HPGDDPP4IDO1RECQLEPHX1 | |
| SCHEMBL1576175 | 0.85 | GPR119 (0.53) | HPGDDPP4RECQLEPHX1NR1H2 | |
| SCHEMBL148385 | 0.85 | GPR119 (0.53) | HPGDDPP4RECQLEPHX1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502393-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| CN-113166157-B | Double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3887376-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502393-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE9A, PDE2A, PDE5A | HPGD 406/4885DPP4 1092/4885IDO1 2092/4885 |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | HPGD 496/4885DPP4 1118/4885IDO1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.